These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26824941)

  • 1. Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development.
    Nuermberger E; Sizemore C; Romero K; Hanna D
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1177-82. PubMed ID: 26824941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Efficacy Testing of New Drug Candidates.
    Nuermberger EL
    Microbiol Spectr; 2017 Jun; 5(3):. PubMed ID: 28643624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.
    Romero K; Clay R; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S5-9. PubMed ID: 26224771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.
    Franzblau SG; DeGroote MA; Cho SH; Andries K; Nuermberger E; Orme IM; Mdluli K; Angulo-Barturen I; Dick T; Dartois V; Lenaerts AJ
    Tuberculosis (Edinb); 2012 Nov; 92(6):453-88. PubMed ID: 22940006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical study of new TB drugs and drug combinations in mouse models.
    Nikonenko BV; Sacksteder KA; Hundert S; Einck L; Nacy CA
    Recent Pat Antiinfect Drug Discov; 2008 Jun; 3(2):102-16. PubMed ID: 18673123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research resources for tuberculosis at the National Institute of Allergy and Infectious Diseases.
    NIH, DMID TB program
    Tuberculosis (Edinb); 2013 Jan; 93(1):6-11. PubMed ID: 23385001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size.
    de Steenwinkel JE; ten Kate MT; de Knegt GJ; Verbrugh HA; van Belkum A; Hernandez-Pando R; Bakker-Woudenberg IA
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1478-84, i. PubMed ID: 22008760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.
    Nikonenko BV; Protopopova M; Samala R; Einck L; Nacy CA
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1563-5. PubMed ID: 17242141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiology. TB--a new target, a new drug.
    Cole ST; Alzari PM
    Science; 2005 Jan; 307(5707):214-5. PubMed ID: 15653490
    [No Abstract]   [Full Text] [Related]  

  • 12. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
    Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candidate anti-tuberculosis medicines and regimens under clinical evaluation.
    Hoelscher M; Barros-Aguirre D; Dara M; Heinrich N; Sun E; Lange C; Tiberi S; Wells C
    Clin Microbiol Infect; 2024 Sep; 30(9):1131-1138. PubMed ID: 38909687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delamanid Kills Dormant Mycobacteria
    Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the development of new tuberculosis drugs and treatment regimens.
    Zumla A; Nahid P; Cole ST
    Nat Rev Drug Discov; 2013 May; 12(5):388-404. PubMed ID: 23629506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon.
    Bhat ZS; Rather MA; Maqbool M; Ahmad Z
    Biomed Pharmacother; 2018 Jul; 103():1733-1747. PubMed ID: 29864964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis drugs: new candidates and how to find more.
    Sala C; Hartkoorn RC
    Future Microbiol; 2011 Jun; 6(6):617-33. PubMed ID: 21707310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and validation of new antitubercular compounds as potential drug leads and probes.
    Goldman RC; Laughon BE
    Tuberculosis (Edinb); 2009 Sep; 89(5):331-3. PubMed ID: 19716767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.